'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Being a 50-something is tricky. Midlife crises may be largely complete, greying hair and ageing ...

"This last decade has been the most ass-kicking and furthering of my life, and it is finally bringing peace," said the actress Benjamin VanHoose is a Staff Editor on the Movies team at PEOPLE. He ...

It’s natural for our hair to turn gray or white with age, but you may also experience other changes to your tresses. That’s where the best hairstyles for women over 50 come into play.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...